If we don’t make money here. When Tom writes his book on this, at least some might make some money off the royalties.

One of the reasons I created a science of leronlimab post. I’m expecting people to come when the bla or deal gets announced.

Usually after hearing about leronlimab, they ask why is the share price so low. They some claim there is no science without knowing the 20 years of research gone into it. Some think all ccr5 antagonists have horrible side effects. Some think maraviroc is already approved, so it doesn’t matter if leronlimab will be. Lots for them to learn imo.